Navigation Links
Insulin may reduce several inflammatory factors induced by bacterial infection
Date:9/8/2010

BUFFALO, N.Y. -- Treating intensive care patients who develop life-threatening bacterial infections, or septicemia, with insulin potentially could reduce their chances of succumbing to the infection, if results of a new preliminary study can be replicated in a larger study.

A paper published online ahead of print in Diabetes Care reports that insulin lowered the amount of inflammation and oxidative stress in study participants who had been injected with a common bacteria, or endotoxin, known as LPS (lipopolysaccharide).

The study was conducted by University at Buffalo endocrinologists at Kaleida Health's Diabetes-Endocrinology Center of Western New York.

LPS, found in the outer membrane of various gram-negative bacteria, is known to increase the ability of the bacteria to cause hemorrhage, necrosis of the kidneys and shock, especially in immune-compromised patients.

The study involved 19 healthy subjects who were injected after an overnight fast with a dose of the endotoxin based on their weight. After the endotoxin injection, 10 participants were infused with insulin (plus dextrose to maintain normal glucose levels), and nine received saline to mimic the insulin infusion.

The infusions continued for six hours following the endotoxin injections. Participants then ate a 900 calorie meal and ate nothing else until the following morning.

Researchers monitored the subjects' temperature, pulse, blood pressure, headaches, body aches and chills for 24 hours following the endotoxin injection. Blood samples were collected one hour before the injection, at the time of injection and at one, two, four, six and 24 hours afterwards.

Monitoring showed that the endotoxin raised body temperature by three degrees -- from 98 to a peak of 101.3 at the four-hour mark, and produced body aches and headaches, which peaked between one and two hours. Results showed that insulin reduced the body-aches score but had no effect on temperature,

In addition, the endotoxin induced a rapid rise in several destructive and inflammatory factors, including reactive oxygen species (free radicals) and products of nitric oxide and fat metabolism. The insulin infusion led to total elimination of several pro-inflammatory factors and to a significant reduction in generation of reactive oxygen species and the products of fat metabolism.

Paresh Dandona, MD, PhD, UB distinguished professor of medicine and senior author on the study, says this study confirms the expectations arising out of the researchers' initial discovery of the anti-inflammatory effect of insulin.

"This study lays the foundation for further studies based on insulin infusion and the normalization of blood glucose concentrations in patients with endotoxemia and septicemia," says Dandona.

"Our endocrinology group demonstrated previously that insulin also has anti-inflammatory and cardioprotective effects in patients who had a heart attack, and we currently are conducting a study on the potential beneficial effects of insulin on acute stroke.

"Clearly, insulin may emerge with roles beyond those conceived when it was discovered in 1921 as a metabolic hormone, and has since been used for the treatment of diabetes to lower and control blood glucose concentrations," Dandona notes.


'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-4606
University at Buffalo
Source:Eurekalert

Related biology news :

1. For insulin sensitive overweight patients, 1 session of exercise improves metabolic health
2. Decreasing insulin resistance prevents obesity-related cardiovascular damage
3. Findings show insulin -- not genes -- linked to obesity
4. Nanodiamonds deliver insulin for wound healing
5. Pitt study finds molecular link between insulin resistance and inflammation
6. Diabetes advance: Researchers find gene that causes resistance to insulin
7. CHEO RI study uses sophisticated genetic engineering to improve insulin-producing beta cells
8. New gene variants associated with glucose, insulin levels, some with diabetes risk
9. Scripps research scientists find new link between insulin and core body temperature
10. Structure of insulins docking point identified
11. Insulin-like signal needed to keep stem cells alive in adult brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2016)... -- SuperCom (NASDAQ:   SPCB ... Public Safety, HealthCare, and Finance sectors announced today that Leaders in ... implement and deploy a community-based supportive services program to reduce recidivism ... further expanding its presence in the state. ... This new program, which is expected to ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/16/2016)... 2016 The global wearable medical device market, in terms ... from USD 5.31 billion in 2016, at a CAGR of 18.0% ... ... advancements in medical devices, launch of a growing number of smartphone-based ... among healthcare providers, and increasing focus on physical fitness. ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... 20, 2017 Ginkgo Bioworks, the organism ... pioneer in the synthesis and assembly of DNA. ... assembling pathway-length synthetic DNA into Ginkgo,s automated organism ... the construction of new organism designs for application ... "Gen9 was founded to significantly increase the world,s ...
(Date:1/19/2017)... HOUSTON , Jan. 19, 2017 ... formation of its Medical/Clinical Advisory Board.  This new ... who enhance the range and depth of expertise ... its novel prenatal diagnostic tests.  These experts are ... guidance for the company,s product development and commercialization ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, ... Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious ... agreement for the merger of PharmAthene and Altimmune ... Novartis Venture Fund, HealthCap, Truffle Capital and Redmont ... and diversified immunotherapeutics company with four clinical stage ...
(Date:1/19/2017)... , ... January 19, 2017 , ... FireflySci Inc. is ... rate. The tremendous growth is accounted to two main factors. The first ... the expanding network of vendors supplying FireflySci products all around the world. , 2016 ...
Breaking Biology Technology: